Takeda, CSL, Other Blood Plasma Firms Team On Hyperimmune COVID-19 Therapy

Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.

3d illustration of red blood cells in the artery
Six partner companies hope to derive a plasma-based COVID therapy from donors who survived the virus

Who: Takeda, CSL Behring, Octapharma, Biotest, Bio Products Laboratory, LFB Biotechnologies

What: Six companies will combine their expertise and resources to develop a plasma-derived therapy for patients with serious complications of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip